CSF2 and cancer: In this cluster randomized clinical trial that included 32 community oncology practices and 2946 adult patients with cancer, primary prophylactic colony-stimulating factor use was high and did not differ significantly between groups (89.2% of patients in the intervention group vs 95.8% of patients in the usual care group).